THROMBOGENICS
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1985-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.thrombogenics.com
Clinical Trials
29
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (26 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
- Conditions
- Retinal TelangiectasisIdiopathic Juxtafoveal Retinal Telangiectasia
- Interventions
- Drug: THR-317 8mg
- First Posted Date
- 2018-09-13
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 8
- Registration Number
- NCT03669393
- Locations
- 🇫🇷
Hôpital Lariboisière, Paris, France
🇫🇷Hôpital Cochin, Paris, France
🇨🇭Hôpital Ophtalmique Jules-Gonin, Lausanne, Switzerland
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
- Conditions
- Diabetes MellitusDiabetic Macular EdemaDiabetic Retinopathy
- Interventions
- Drug: THR-687 dose level 3Drug: THR-687 dose level 2Drug: THR-687 dose level 1
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 12
- Registration Number
- NCT03666923
- Locations
- 🇺🇸
Retina Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Center for Retina and Macular Disease, Winter Haven, Florida, United States
🇺🇸Midwest Eye Institute, Indianapolis, Indiana, United States
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
- Conditions
- Diabetes MellitusDiabetic Macular EdemaDiabetic Retinopathy
- Interventions
- Drug: THR-149 dose level 1Drug: THR-149 dose level 2Drug: THR-149 dose level 3
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 12
- Registration Number
- NCT03511898
- Locations
- 🇺🇸
Retina Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Ophthalmic Consultants of Boston, Boston, Massachusetts, United States
🇺🇸Sierra Eye Associates, Reno, Nevada, United States
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
- Conditions
- Macular EdemaDiabetic Retinopathy
- Interventions
- Drug: Anti-PlGF recombinant monoclonal antibody, 4mg doseDrug: Anti-PlGF recombinant monoclonal antibody, 8mg dose
- First Posted Date
- 2017-03-06
- Last Posted Date
- 2018-04-17
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 49
- Registration Number
- NCT03071068
A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR
- Conditions
- Posterior Vitreous DetachmentDiabetic RetinopathyDisease Progression
- Interventions
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- ThromboGenics
- Target Recruit Count
- 48
- Registration Number
- NCT02681809
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
EMA's CHMP Recommends Approval of Novartis' Jetrea for Vitreomacular Traction Treatment
Novartis' eye care division Alcon receives positive CHMP opinion for Jetrea (ocriplasmin) to treat vitreomacular traction and associated macular holes in European patients.